Table 1. Demographic, clinical feature, disease activity, comorbidity by race of EMRAC patients
| African-American | Caucasian | Hispanic | Other | Total | P | |
|---|---|---|---|---|---|---|
| N | 154 | 183 | 111 | 54 | 502 | |
| Age (years) | 58.5 (14.0) | 54.6 (18.4) | 54.2 (15.0) | 49.1 (16.0) | 55.1 (16.4) | 0.003* |
| Duration (years) | 8.9 (8.9) | 10.0 (10.9) | 8.9 (9.3) | 8.2 (8.7) | 9.2 (9.7) | 0.863 |
| Education (years) | 13.8 (3.3) | 15.7 (2.9) | 12.4 (3.9) | 15.7 (3.6) | 14.4 (3.6) | <0.001* |
| Female [N (%)] | 137 (89.0%) | 153 (83.6%) | 89 (80.2%) | 47 (13.0%) | 426 (84.9%) | 0.230 |
| RAPID3 [0-30] (N=461) | 12.1 (7.2) | 10.0 (6.8) | 13.5 (7.2) | 10.4 (7.8) | 11.5 (7.3) | 0.001* |
| DAS28 [0-10] (N=127 ) | 3.6 (1.4) | 3.7 (1.5) | 3.0 (1.9) | 4.1 (1.8) | 3.6 (1.5) | 0.330 |
| CDAI [0-76] (N=169) | 12.2 (11.5) | 14.5 (10.9) | 10.5 (9.9) | 15.5 (14.4) | 13.0 (11.5) | 0.347 |
| Prednisone [N (%)] | 66 (42.9%) | 60 (32.8%) | 40 (36.0%) | 18 (33.3%) | 184 (36.7%) | 0.266 |
| DMARD [N (%)] | 127 (82.5%) | 117 (63.9%) | 77 (69.4%) | 40 (74.1%) | 361 (71.9%) | 0.002* |
| Biologic [N (%)] | 30 (19.5%) | 74 (40.4%) | 46 (41.4%) | 19 (35.2%) | 169 (33.7%) | <0.001* |
| Comorbidities [N (%)] | ||||||
| Hypertension | 63 (44.4%) | 35 (25.0%) | 20 (22.7%) | 12 (31.6%) | 130 (31.9%) | <0.001* |
| Asthma | 9 (10.2%) | 14 (24.6%) | 13 (65.0%) | 5 (31.2%) | 41 (22.6%) | <0.001* |
| Diabetes | 24 (25.8%) | 6 (11.8%) | 11 (64.7%) | 4 (28.6%) | 45 (25.7%) | <0.001* |
| Cigarette Use (Ever) | 36 (36.7%) | 42 (16.4%) | 17 (34.0%) | 3 (13.6%) | 98 (37.6%) | 0.032* |